Published in Nucl Med Biol on October 01, 2010
Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics (2012) 1.33
Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol (2012) 1.22
T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment. PLoS One (2012) 1.05
Radiolabelled peptides for oncological diagnosis. Eur J Nucl Med Mol Imaging (2012) 0.93
A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer. J Nucl Med (2013) 0.89
64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer. Nucl Med Biol (2012) 0.87
Development of copper based drugs, radiopharmaceuticals and medical materials. Biometals (2012) 0.87
Comparative study of 64Cu/NOTA-[D-Tyr6,βAla11,Thi13,Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging. EJNMMI Res (2012) 0.83
In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer. Nucl Med Biol (2012) 0.81
In vitro and in vivo evaluation of melanin-binding decapeptide 4B4 radiolabeled with 177Lu, 166Ho, and 153Sm radiolanthanides for the purpose of targeted radionuclide therapy of melanoma. Cancer Biother Radiopharm (2011) 0.80
A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nucl Med Biol (2013) 0.80
Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment. Expert Opin Ther Targets (2016) 0.79
Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer. Nucl Med Biol (2014) 0.78
[64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A (2007) 1.73
In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med (2007) 1.52
Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med (2005) 1.41
In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer (2002) 1.37
Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med (2003) 1.32
Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol (2005) 1.29
203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med (2008) 1.22
Modification of the structure of a metallopeptide: synthesis and biological evaluation of (111)In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues. J Med Chem (2002) 1.21
Radiometals for combined imaging and therapy. Chem Rev (2012) 1.14
Tumor-targeting properties of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol (2005) 1.12
TLD assessment of mouse dosimetry during microCT imaging. Med Phys (2008) 1.11
In vitro and in vivo analysis of [(64)Cu-NO2A-8-Aoc-BBN(7-14)NH(2)]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors. Nucl Med Biol (2009) 1.07
Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res (2004) 1.04
Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol (2008) 1.02
Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl Med Biol (2003) 1.01
Microimaging characterization of a B16-F10 melanoma metastasis mouse model. Mol Imaging (2006) 1.01
Radiochemical investigations of (99m)Tc-N(3)S-X-BBN[7-14]NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug Chem (2003) 1.00
In vitro and in vivo evaluation of a novel 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys). Bioconjug Chem (2007) 1.00
Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model. Bioconjug Chem (2008) 0.99
True radiotracers: Cu-64 targeting vectors based upon bombesin peptide. Nucl Med Biol (2009) 0.98
Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis. Cell Cycle (2010) 0.98
Near-infrared fluorescence imaging of gastrin releasing peptide receptor targeting in prostate cancer lymph node metastases. Prostate (2012) 0.95
Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector. Bioconjug Chem (2008) 0.95
In vitro and in vivo evaluation of Alexa Fluor 680-bombesin[7-14]NH2 peptide conjugate, a high-affinity fluorescent probe with high selectivity for the gastrin-releasing peptide receptor. Mol Imaging (2007) 0.94
Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu. Bioconjug Chem (2011) 0.92
Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm (2006) 0.90
PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog. J Nucl Med (2012) 0.90
Flavin mononucleotide (FMN)-based fluorescent protein (FbFP) as reporter for gene expression in the anaerobe Bacteroides fragilis. FEMS Microbiol Lett (2011) 0.89
Development of high-specific-activity (68)Ga-labeled DOTA-rhenium-cyclized alpha-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors. Nucl Med Biol (2009) 0.88
Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu. Bioconjug Chem (2006) 0.87
64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer. Nucl Med Biol (2012) 0.87
In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas. J Labelled Comp Radiopharm (2009) 0.86
Chemical synthesis of Escherichia coli ST(h) analogues by regioselective disulfide bond formation: biological evaluation of an (111)In-DOTA-Phe(19)-ST(h) analogue for specific targeting of human colon cancers. Bioconjug Chem (2002) 0.85
Aminocarboxylate complexes and octreotide complexes with no carrier added 177Lu, 166Ho and 149Pm. Nucl Med Biol (2003) 0.85
Pm-149 DOTA bombesin analogs for potential radiotherapy. in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2). Nucl Med Biol (2002) 0.85
Organometallic 99mTc(III) '4 + 1' bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies. Bioconjug Chem (2007) 0.85
Molecular imaging of bcl-2 expression in small lymphocytic lymphoma using 111In-labeled PNA-peptide conjugates. J Nucl Med (2008) 0.84
Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin. Nucl Med Biol (2006) 0.84
The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals. In Vivo (2007) 0.84
Extraction of pertechnetate and perrhenate from water with deep-cavity [CpFe(arene)](+)-derivatized cyclotriveratrylenes. Inorg Chem (2002) 0.84
Phenotypic plasticity and function of the hard palate in growing rabbits. Anat Rec (Hoboken) (2009) 0.84
Evaluation of [99mTc-(CO)3-X-Y-Bombesin(7-14)NH2] conjugates for targeting gastrin-releasing peptide receptors overexpressed on breast carcinoma. Anticancer Res (2010) 0.84
Synthesis and characterization of novel rhenium(V) tetradentate N2O2 Schiff base monomer and dimer complexes. Inorg Chem (2003) 0.84
Reactivity of rhenium(V) oxo Schiff base complexes with phosphine ligands: rearrangement and reduction reactions. Inorg Chem (2005) 0.84
Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl Med Biol (2004) 0.83
Bombesin analogues for gastrin-releasing peptide receptor imaging. Nucl Med Biol (2012) 0.83
Bifunctional phage-based pretargeted imaging of human prostate carcinoma. Nucl Med Biol (2009) 0.83
Pyrazolyl conjugates of bombesin: a new tridentate ligand framework for the stabilization of fac-[M(CO)3]+ moiety. Nucl Med Biol (2006) 0.82